Advertisement

Molecular Biotechnology

, Volume 19, Issue 2, pp 169–177 | Cite as

Virus-like particles as vaccine adjuvants

  • Sarah C. Gilbert
Protocol

Abstract

Virus-like particles (VLPs) consist of one or more viral coat proteins that assemble into particles. They can be taken up by antigen presenting cells (APC), peptides derived from them are presented on MHC class I molecules at the cell surface, and thereby prime a CD8+ T cell response, either against the particle-forming protein itself (such as Hepatitis B surface antigen) or additional peptide sequences that are produced as fusions with the particle-forming protein. This article describes the preparation of Ty-VLPs in Saccharomyces cerevisiae, a system that can easily be handled in the laboratory or scaled up for manufacture, and is safe in use.

Index Entries

Virus-like particle Ty-VLP recombinant sub-unit vaccine CTL 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schneider, J., Gilbert, S. C., Blanchard, T. J., et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397–402.PubMedCrossRefGoogle Scholar
  2. 2.
    Dupuis, M., Denis-Mize, K., Woo, C., et al. (2000) Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 165, 2850–2858.PubMedGoogle Scholar
  3. 3.
    Schirmbeck, R., Melber, K., and Reimann, J. (1995) Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restriced epitope presentation. Eur. J. Immunol. 25, 1063–1070.PubMedCrossRefGoogle Scholar
  4. 4.
    Schirmbeck, R., Deml, L., Melber, K., Wolf, H., Wagner, R., and Reimann, J. (1995) Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 13, 857–865.PubMedCrossRefGoogle Scholar
  5. 5.
    Schirmbeck, R., Melber, K., Kurober, A., Janowicz, J., and Reimann, J. (1994) Immunization with soluble hepatitis B virus sàzface protein elicits murine H-2 Class I-restricted CD8+ cytotoxic T lymphocyte resonses in vivo. J. Immunol. 152, 1110–1119.PubMedGoogle Scholar
  6. 6.
    Harris, S., Woodrow, S. A., Gearing, A. J. H., Adams, S. A., Kingsman, A. J., and Layton, G. T. (1996) The effects of adjuvants on CTL induction by V3:Ty-virus-like-particles (V3-VLPs) in mice. Vaccine 14, 971–976.PubMedCrossRefGoogle Scholar
  7. 7.
    Kelleher, A. D., Roggensack, M., Jaramillo, A. B., et al. (1998) Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like aprticle, combined with zidovudine, in asymptomatic subjects. AIDS 12, 175–185.PubMedCrossRefGoogle Scholar
  8. 8.
    Ball, J. M., Hardy, M. E., Atmat, R. L., Conner, M. E., and Estes, M. K. (1998) Oral immunisation with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72, 1345–1353.PubMedGoogle Scholar
  9. 9.
    O’Neal, C. M., Crawford, S. E., Estes, M. K., and Conner, M. E. (1997) Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71, 8707–8717.PubMedGoogle Scholar
  10. 10.
    Sharma, A., Rao, Z., Fry, E., et al. (1997) Specific interactions between human integrin alpha v beta 3 and chimeric hepatitis B virus core particles bearing the receptor-binding epitope of foot-and-mouth disease virus. Virology 239, 150–157.PubMedCrossRefGoogle Scholar
  11. 11.
    Dalsgaard, K., Uttenthal, A., Jones, T. D., et al. (1997) Plant-derived vaccine protects target animals against a viral disease. Nat. Biotechnol. 15, 248–252.PubMedCrossRefGoogle Scholar
  12. 12.
    Ballou, W. R., Kester, K. E., Stoute, J. A., and Heppner, D. G. (1999) Malaria vaccines: triumphs or tribulations? Parassitologia 41, 403–408.PubMedGoogle Scholar
  13. 13.
    Doherty, J. F., Pinder, M., Tornieporth, N., et al. (1999) A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semiimmune adults in The Gambia. Am. J. Trop. Med. Hyg. 61, 865–868.PubMedGoogle Scholar
  14. 14.
    Lalvani, A., Moris, P., Voss, G., et al. (1999) Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180, 1656–1664.PubMedCrossRefGoogle Scholar
  15. 15.
    Stoute, J. A., et al. (1998) Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139–1144.PubMedGoogle Scholar
  16. 16.
    Mikhailov, M., Monastyrskaya, K., Bakker, T., and Roy, P. (1996) A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules. Virology 217, 323–331.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenstone, H. L., Nieland, J. D., de Visser, K. E., et al. (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95, 1800–1805.PubMedCrossRefGoogle Scholar
  18. 18.
    Burns, N. R., Gilmour, E. M., Kingsman, S. M., Kingsman, A. J., and Adams, S. E. (1994) Production and purification of hybrid Ty-VLPs. Mol. Biotechnol. 1, 137–145.PubMedCrossRefGoogle Scholar
  19. 19.
    Gilbert, S. C., Plebanski, M., Harris, S. J., et al. (1997) A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15, 1280–1284.PubMedCrossRefGoogle Scholar
  20. 20.
    Allsopp, C. E., Plebanski, M., Gilbert, S., et al. (1996) Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26, 1951–1959.PubMedCrossRefGoogle Scholar
  21. 21.
    Klavinskis, L. S., Bergmeier, L. A., Gao, L., et al. (1996) Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph notes. J. Immunol. 157, 2521–2527.PubMedGoogle Scholar
  22. 22.
    Griffiths, J. C., Berrie, E. L., Holdsworth, L. N., et al. (1991) Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty virus-like particles in a clinically relevant adjuvant. J. Virol. 65, 450–456.PubMedGoogle Scholar
  23. 23.
    Weber, J., Cheinsong Popov, R., Callow, D., et al. (1995) Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 13, 831–834.PubMedCrossRefGoogle Scholar
  24. 24.
    Martin, S. J., Vyakarnam, A., Cheinsong Popov, R., et al. (1993) Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 7, 1315–1323.PubMedCrossRefGoogle Scholar
  25. 25.
    Gilbert, S. C. and Hill, A. V. S. (1997) Protein particle vaccines against malaria. Parasitology Today 13, 302–306.PubMedCrossRefGoogle Scholar
  26. 26.
    Lundblad, V. (1997) in Current Protocols in Molecular Biology (Wiley, NY).Google Scholar
  27. 27.
    Layton, G. T., Harris, S. J., Myhan, J., et al. (1996) Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 87, 171–178.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  1. 1.Wellcome Trust Centre for Human GeneticsHeadington, OxfordUK

Personalised recommendations